CDF IMAGES

  • Portfolio
    • All Galleries
    • Search
    • Cart
    • Lightbox
    • Client Area
  • Services
    • Commercial and Event Photography
    • Portrait Photography
    • Product Catalogue
    • General Terms and Conditions
    • Commercial Terms and Conditions of Business
  • About
  • Contact
  • Facebook
  • Twitter
x

Search Results

Refine Search
Match all words
Match any word
Prints
Personal Use
Royalty-Free
Rights-Managed
(leave unchecked to
search all images)
23 images found
twitterlinkedinfacebook

Loading ()...

  • Livingston, Scotland, UK. 21 July 2020<br />
Pictured: The factory of pharmaceutical company Valneva, situated in Livingston, Scotland, is developing an inactivated virus vaccine and the government is expected to contribute to the cost of clinical trials.<br />
<br />
Funding is also being negotiated to expand the Scottish facility to allow production of up to 100 million doses for the UK and around the world. Credit: Colin D Fisher/CDFIMAGES.COM
    CDF_7367.jpg
  • Livingston, Scotland, UK. 21 July 2020<br />
Pictured: The factory of pharmaceutical company Valneva, situated in Livingston, Scotland, is developing an inactivated virus vaccine and the government is expected to contribute to the cost of clinical trials.<br />
<br />
Funding is also being negotiated to expand the Scottish facility to allow production of up to 100 million doses for the UK and around the world. Credit: Colin D Fisher/CDFIMAGES.COM
    _CDF5300.jpg
  • Livingston, Scotland, UK. 21 July 2020<br />
Pictured: The factory of pharmaceutical company Valneva, situated in Livingston, Scotland, is developing an inactivated virus vaccine and the government is expected to contribute to the cost of clinical trials.<br />
<br />
Funding is also being negotiated to expand the Scottish facility to allow production of up to 100 million doses for the UK and around the world. Credit: Colin D Fisher/CDFIMAGES.COM
    CDF_7368.jpg
  • Livingston, Scotland, UK. 21 July 2020<br />
Pictured: The factory of pharmaceutical company Valneva, situated in Livingston, Scotland, is developing an inactivated virus vaccine and the government is expected to contribute to the cost of clinical trials.<br />
<br />
Funding is also being negotiated to expand the Scottish facility to allow production of up to 100 million doses for the UK and around the world. Credit: Colin D Fisher/CDFIMAGES.COM
    _CDF5310.jpg
  • Livingston, Scotland, UK. 21 July 2020<br />
Pictured: The factory of pharmaceutical company Valneva, situated in Livingston, Scotland, is developing an inactivated virus vaccine and the government is expected to contribute to the cost of clinical trials.<br />
<br />
Funding is also being negotiated to expand the Scottish facility to allow production of up to 100 million doses for the UK and around the world. Credit: Colin D Fisher/CDFIMAGES.COM
    _CDF5305.jpg
  • Livingston, Scotland, UK. 21 July 2020<br />
Pictured: The factory of pharmaceutical company Valneva, situated in Livingston, Scotland, is developing an inactivated virus vaccine and the government is expected to contribute to the cost of clinical trials.<br />
<br />
Funding is also being negotiated to expand the Scottish facility to allow production of up to 100 million doses for the UK and around the world. Credit: Colin D Fisher/CDFIMAGES.COM
    CDF_7361.jpg
  • Livingston, Scotland, UK. 21 July 2020<br />
Pictured: The factory of pharmaceutical company Valneva, situated in Livingston, Scotland, is developing an inactivated virus vaccine and the government is expected to contribute to the cost of clinical trials.<br />
<br />
Funding is also being negotiated to expand the Scottish facility to allow production of up to 100 million doses for the UK and around the world. Credit: Colin D Fisher/CDFIMAGES.COM
    _CDF5302.jpg
  • Livingston, Scotland, UK. 21 July 2020<br />
Pictured: The factory of pharmaceutical company Valneva, situated in Livingston, Scotland, is developing an inactivated virus vaccine and the government is expected to contribute to the cost of clinical trials.<br />
<br />
Funding is also being negotiated to expand the Scottish facility to allow production of up to 100 million doses for the UK and around the world. Credit: Colin D Fisher/CDFIMAGES.COM
    CDF_7354.jpg
  • Livingston, Scotland, UK. 21 July 2020<br />
Pictured: The factory of pharmaceutical company Valneva, situated in Livingston, Scotland, is developing an inactivated virus vaccine and the government is expected to contribute to the cost of clinical trials.<br />
<br />
Funding is also being negotiated to expand the Scottish facility to allow production of up to 100 million doses for the UK and around the world. Credit: Colin D Fisher/CDFIMAGES.COM
    _CDF5309.jpg
  • Livingston, Scotland, UK. 21 July 2020<br />
Pictured: The factory of pharmaceutical company Valneva, situated in Livingston, Scotland, is developing an inactivated virus vaccine and the government is expected to contribute to the cost of clinical trials.<br />
<br />
Funding is also being negotiated to expand the Scottish facility to allow production of up to 100 million doses for the UK and around the world. Credit: Colin D Fisher/CDFIMAGES.COM
    _CDF5303.jpg
  • Livingston, Scotland, UK. 21 July 2020<br />
Pictured: The factory of pharmaceutical company Valneva, situated in Livingston, Scotland, is developing an inactivated virus vaccine and the government is expected to contribute to the cost of clinical trials.<br />
<br />
Funding is also being negotiated to expand the Scottish facility to allow production of up to 100 million doses for the UK and around the world. Credit: Colin D Fisher/CDFIMAGES.COM
    CDF_7349.jpg
  • Livingston, Scotland, UK. 21 July 2020<br />
Pictured: The factory of pharmaceutical company Valneva, situated in Livingston, Scotland, is developing an inactivated virus vaccine and the government is expected to contribute to the cost of clinical trials.<br />
<br />
Funding is also being negotiated to expand the Scottish facility to allow production of up to 100 million doses for the UK and around the world. Credit: Colin D Fisher/CDFIMAGES.COM
    _CDF5304.jpg
  • Livingston, Scotland, UK. 21 July 2020<br />
Pictured: The factory of pharmaceutical company Valneva, situated in Livingston, Scotland, is developing an inactivated virus vaccine and the government is expected to contribute to the cost of clinical trials.<br />
<br />
Funding is also being negotiated to expand the Scottish facility to allow production of up to 100 million doses for the UK and around the world. Credit: Colin D Fisher/CDFIMAGES.COM
    _CDF5297.jpg
  • Livingston, Scotland, UK. 21 July 2020<br />
Pictured: The factory of pharmaceutical company Valneva, situated in Livingston, Scotland, is developing an inactivated virus vaccine and the government is expected to contribute to the cost of clinical trials.<br />
<br />
Funding is also being negotiated to expand the Scottish facility to allow production of up to 100 million doses for the UK and around the world. Credit: Colin D Fisher/CDFIMAGES.COM
    _CDF5295.jpg
  • Livingston, Scotland, UK. 21 July 2020<br />
Pictured: The factory of pharmaceutical company Valneva, situated in Livingston, Scotland, is developing an inactivated virus vaccine and the government is expected to contribute to the cost of clinical trials.<br />
<br />
Funding is also being negotiated to expand the Scottish facility to allow production of up to 100 million doses for the UK and around the world. Credit: Colin D Fisher/CDFIMAGES.COM
    CDF_7358.jpg
  • Livingston, Scotland, UK. 21 July 2020<br />
Pictured: The factory of pharmaceutical company Valneva, situated in Livingston, Scotland, is developing an inactivated virus vaccine and the government is expected to contribute to the cost of clinical trials.<br />
<br />
Funding is also being negotiated to expand the Scottish facility to allow production of up to 100 million doses for the UK and around the world. Credit: Colin D Fisher/CDFIMAGES.COM
    _CDF5298.jpg
  • Livingston, Scotland, UK. 21 July 2020<br />
Pictured: The factory of pharmaceutical company Valneva, situated in Livingston, Scotland, is developing an inactivated virus vaccine and the government is expected to contribute to the cost of clinical trials.<br />
<br />
Funding is also being negotiated to expand the Scottish facility to allow production of up to 100 million doses for the UK and around the world. Credit: Colin D Fisher/CDFIMAGES.COM
    _CDF5294.jpg
  • Livingston, Scotland, UK. 21 July 2020<br />
Pictured: The factory of pharmaceutical company Valneva, situated in Livingston, Scotland, is developing an inactivated virus vaccine and the government is expected to contribute to the cost of clinical trials.<br />
<br />
Funding is also being negotiated to expand the Scottish facility to allow production of up to 100 million doses for the UK and around the world. Credit: Colin D Fisher/CDFIMAGES.COM
    CDF_7360.jpg
  • Livingston, Scotland, UK. 21 July 2020<br />
Pictured: The factory of pharmaceutical company Valneva, situated in Livingston, Scotland, is developing an inactivated virus vaccine and the government is expected to contribute to the cost of clinical trials.<br />
<br />
Funding is also being negotiated to expand the Scottish facility to allow production of up to 100 million doses for the UK and around the world. Credit: Colin D Fisher/CDFIMAGES.COM
    _CDF5306.jpg
  • Livingston, Scotland, UK. 21 July 2020<br />
Pictured: The factory of pharmaceutical company Valneva, situated in Livingston, Scotland, is developing an inactivated virus vaccine and the government is expected to contribute to the cost of clinical trials.<br />
<br />
Funding is also being negotiated to expand the Scottish facility to allow production of up to 100 million doses for the UK and around the world. Credit: Colin D Fisher/CDFIMAGES.COM
    _CDF5311.jpg
  • Livingston, Scotland, UK. 21 July 2020<br />
Pictured: The factory of pharmaceutical company Valneva, situated in Livingston, Scotland, is developing an inactivated virus vaccine and the government is expected to contribute to the cost of clinical trials.<br />
<br />
Funding is also being negotiated to expand the Scottish facility to allow production of up to 100 million doses for the UK and around the world. Credit: Colin D Fisher/CDFIMAGES.COM
    _CDF5312.jpg
  • Livingston, Scotland, UK. 21 July 2020<br />
Pictured: The factory of pharmaceutical company Valneva, situated in Livingston, Scotland, is developing an inactivated virus vaccine and the government is expected to contribute to the cost of clinical trials.<br />
<br />
Funding is also being negotiated to expand the Scottish facility to allow production of up to 100 million doses for the UK and around the world. Credit: Colin D Fisher/CDFIMAGES.COM
    _CDF5307.jpg
  • Livingston, Scotland, UK. 21 July 2020<br />
Pictured: The factory of pharmaceutical company Valneva, situated in Livingston, Scotland, is developing an inactivated virus vaccine and the government is expected to contribute to the cost of clinical trials.<br />
<br />
Funding is also being negotiated to expand the Scottish facility to allow production of up to 100 million doses for the UK and around the world. Credit: Colin D Fisher/CDFIMAGES.COM
    CDF_7363.jpg